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Abstract: Recently, angiogenesis and pulmonary vascular remodeling in COPD has been 
investigated. It has been hypothesized that endothelial dysfunction might be an initiating event 
that promotes vessel remodeling in COPD.
Inﬂ  ammatory tissue- a pivotal pathological feature of COPD- often hypoxic, can induce 
angiogenesis through upregulation of factors such as VEGF or FGF and regulators of angiogen-
esis such as chemokines (CXC family), acting either as angiogenic or angiostatic. Angiopoietins 
are distinct molecules that act in association with VEGF at different stages of angiogenic process. 
The regulation of angiogenesis is determined by a dual, yet opposing balance of angiogenic and 
angiostatic factors that promote or inhibit neovascularization, respectively, not yet elucidated 
in detail in COPD.
Recent studies suggested an increased expression of VEGF in pulmonary muscular arteries 
of patients with moderate COPD and also in smokers with normal lung function. This was also 
associated with enlargement of the arterial wall. However, in patients with severe emphysema, 
the expression of VEGF tended to be low, despite intense vascular remodelling. Furthermore, 
it has been suggested that VEGF might be involved in the pathogenesis of emphysema through 
apoptotic mechanisms. Experimental studies showed that the lung microvascular endothelial 
cells (including the alveolar septal capillary cells) are particularly vulnerable and dependent on 
VEGF for their survival. Apoptosis of endothelial, leading to the loss of capillaries may well 
be a central mechanism in patients with emphysema and muscle wasting.
This review article summarizes the current knowledge regarding the contribution of vascu-
lar remodeling, as well as the pathogenetic and therapeutic implications of pivotal angiogenic 
mediators, in COPD.
Keywords: angiogenic, angiostatic, growth factors, CXC chemokines, CC chemokines, 
COPD
Deﬁ  nitions – implication of angiogenesis
in the pathogenesis of lung diseases
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease 
state characterised by airﬂ  ow limitation that is not fully reversible. The airﬂ  ow limita-
tion is usually progressive and is associated with an abnormal inﬂ  ammatory response 
of the lungs to noxious particles or gases, primarily caused by cigarette smoking. 
Although COPD affects the lungs, it also produces signiﬁ  cant systemic consequences 
(Celli et al 2004; Pauwels and Rabe 2004).
The disease ranks among the top ﬁ  ve leading causes of death and it is estimated that 
it will be in the mortality top three by 2020. The main risk factor is tobacco smoking 
which is associated with 80% of COPD cases. However, only 15%–20% of the smokers 
develop COPD, pointing to other susceptibility factors (Siafakas and Tzortzaki 2002). 
The cause of response variability of the lung to tobacco exposure remains largely unclear. 
Research in the past two decades exhibited pathological features of COPD patients 
comprising lung tissue remodeling-like changes in mucosal tissue, ﬁ  ber types and/or International Journal of COPD 2007:2(4) 454
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ﬁ  brosis, pulmonary and systemic inﬂ  ammation, lung vascular 
remodeling, and angiogenesis (Jeffery 2001a, 2004).
Angiogenesis is the growth of new blood vessels from exist-
ing ones, whereas microvascular remodeling involves structural 
alterations-usually enlargement-of arterioles, capillaries or 
venules, without the formation of new vessels (McDonald 2001; 
Walsh and Pearson 2001). Both types of change in the micro-
vasculature result from endothelial cell proliferation and often 
occur together, but they represent different phenomena and 
responses to different stimuli. In addition, they are instrumen-
tal phenomena under physiologic and pathologic conditions. 
Physiologic conditions include embryogenesis, growth, and 
tissue repair after injury and the female reproductive cycle.
The literature on angiogenesis and vascular remodeling in 
human airway disease is relatively sparse, while the mecha-
nisms and consequences of the changes are just beginning 
to be elucidated. In a model of chronic airway inﬂ  ammation 
produced by Mycoplasma pulmonis infection on the airways 
of mice or rats (McDonald 1999; McDonald 2001), angio-
genesis and microvascular remodeling create vessels that 
mediate leukocyte inﬂ  ux and leak plasma proteins into the 
airway mucosa. These vascular changes are driven by the 
immune response to the organisms.
Interestingly, angiogenesis and microvascular remodeling 
are elements of the tissue remodeling in tumors (Strieter et al 
2004). A role for angiogenesis in enhancing tumor growth is 
now widely accepted, and a variety of anti-angiogenic agents 
are in clinical development. Furthermore, angiogenesis may 
contribute to the pathogenesis of interstitial lung diseases 
(Tzouvelekis et al 2006). Recent theories implicate recurrent 
injurious exposure, imbalance that shifts Th1/Th2 equilibrium 
towards Th2 immunity and angiogenesis in the pathogenesis 
of pulmonary ﬁ  brosis, both in human and experimental studies 
(Antoniou et al 2006; Tzouvelekis et al 2006).
Angiogenesis is an important event both in the develop-
ment of allergic inﬂ  ammation and in the pathophysiology of 
tissue remodeling in atopic diseases (Li and Wilson 1997; 
Redington et al 2001; Hoshino et al 2001a, 2001b, Asai et al 
2002; Lee et al 2004). Previous studies suggested an increased 
number of bronchial vessels in asthma where increased colla-
gen IV staining, a marker of new vessels, was seen in bronchial 
biopsies of asthmatic airways compared with controls (Orsida 
et al 1999; Orsida et al 2001). Subsequent studies by the same 
group and by Salvato and coworkers have conﬁ  rmed the pres-
ence of angiogenesis in the bronchial circulation in asthma 
(Salvato 2001). Recent research showed that an imbalance in 
favor of proangiogenic factors leads to the abnormal growth 
of new blood vessels in asthma. This may then contribute to 
swelling and stiffening of the airway wall and hence affect 
airway obstruction.
While in asthma angiogenesis is well documented, only 
a few studies have directly shown that angiogenesis and 
vascular remodeling occur in COPD. The structures most 
affected, in COPD, are the airways (thickening, ﬁ  brosis, 
loss of alveolar-bronchiolar attachments, and stenosis) and 
the alveolar component [lung parenchyma (in emphysema)]. 
Table 1 summarizes human studies investigating angiogen-
esis and vascular remodeling in COPD.
Angiogenesis in COPD
Airway component
Kranenburg and colleagues showed that COPD is associated 
with increased expression of vascular endothelial growth 
factor (VEGF) in the bronchial, bronchiolar, and alveolar 
epithelium and in bronchiolar macrophages, as well as, 
airway smooth muscle and vascular smooth muscle cells in 
both the bronchiolar and alveolar regions (Kranenburg et al 
2005a). The authors postulated that VEGF and its receptor 
system may contribute to the maintenance of endothelial and 
epithelial cell viability in response to injury. On the contrary, 
a previous report, only in emphysematous patients, showed 
that VEGF and its receptor VEGF-R2 were decreased in 
total lung extracts of emphysematous lungs (Kasahara et al 
2000). In addition, the involvement of bronchial vasculature 
in the airway remodeling occurring in symptomatic patients 
smokers with normal lung function and with COPD has been 
recently investigated (Calabrese et al 2006). In order to evalu-
ate whether an angiogenic process occurs in the airways of 
Table 1 Recent human studies investigating angiogenesis and 
vascular remodeling in COPD
Investigator   Tissue samples  Studied 
(year) Sample  size  parameters
Kranenburg et al  Central and peripheral   VEGF
(2005)  lung tissues 14 patients-  FLT-1
  14 controls  KDR/Flk -1
Hashimoto et al   Lung specimens  VEGF
(2005)  11 patients-8 controls  bFGF
Calabrese et al   Bronchial specimens  VEGF
(2006)  18 patients-8 controls  Integrin αvβ3
Santos et al   Lung specimens-pulmonary  VEGF
(2003) muscular  arteries 
  19 nonsmokers-21 smokers-28
 moderateCOPD-severe   
 emphysema
Peinado et al   Pulmonary arteries from   VEGF
(2006)  lung specimens 9 COPD   VEGFR2
 patients-6  controlsInternational Journal of COPD 2007:2(4) 455
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symptomatic smokers with and without COPD, the authors 
have also investigated, by immunohistochemistry, the num-
ber of integrin αvβ3 positive vessels. Recent knowledge 
suggests that VEGF and integrin αvβ3 may collaborate to 
vessel formation (Byzova et al 2000, Liu et al 2003). This 
study showed an increase in bronchial vascularity, expressed 
in terms of both number of vessels and vascular area, 
compared to healthy non-smokers in the central airways of 
symptomatic smokers with normal lung function and with 
moderate COPD (Calabrese et al 2006). The increased αvβ3 
expression detected on bronchial vessels associated to the 
higher VEGF expression suggests that these two molecules 
could cooperate in the angiogenetic process occurring in the 
airways of symptomatic smokers with normal lung function 
and with COPD. Furthemore, Hashimoto and colleagues 
compared small and large airways in Asthma and COPD, and 
found that the number of vessels in the medium and small 
airways in patients with asthma showed a greater increase 
than in patients with COPD and control subjects, while the 
vascular area in the small airways was increased in COPD 
patients versus control subjects (Hashimoto et al 1997).
Alveolar component
Inﬂ  ammation- a pivotal pathological feature of COPD- may 
promote angiogenesis in a number of ways (Walsh and 
Rearson 2001; Risau 1997) (Figure 1). Firstly, airway inﬂ  am-
mation in COPD is characterised by an inﬂ  ux of inﬂ  ammatory 
cells –predominantly neutrophils, macrophages and CD8+ 
T lymphocytes- in the lumen and wall of the bronchial and 
bronchiolar airways and parenchyma (Jeffery 2001a, 2001b, 
2004; Saetta et al 2001). Secondly, several studies have 
reported a thickened bronchiolar wall and airway remodeling 
with peribronchiolar ﬁ  brosis, an increase in airway smooth 
muscle mass, and emphysema (Cosio et al 1980; Lang et al 
1994; Jeffery 2001b). Additionally, inﬂ  ammatory tissue 
is often hypoxic, and hypoxia can induce angiogenesis 
through upregulation of factors such as VEGF or Fibroblast 
growth factor (FGF). Extravasated plasma proteins such 
as ﬁ  brinogen products may stimulate neovascularisation 
(Jeffery 1998, 2001b). Inﬂ  ammatory cells such as macro-
phages, lymphocytes, mast cells and ﬁ  broblasts, and the 
angiogenic mediators they produce, can stimulate vessel 
growth. Many proinﬂ  ammatory cytokines, such as tumour 
necrosis factor (TNF)-α, may have angiogenic activity in 
addition to proinﬂ  ammatory activity (Strieter et al 2004; 
Tzouvelekis et al 2006). Increased blood ﬂ  ow itself may stim-
ulate angiogenesis through shear stresses on the endothelium 
(Figure 1). Inﬂ  ammation also may upregulate the expression 
of angiogenic growth factors (VEGF, FGF) and regulators of 
angiogenesis such as chemokines (CXC family), acting either 
as angiogenic or angiostatic factors (Tzouvelekis et al 2006). 
Growth factors like epidermal growth factor (EGF), FGF 
and VEGF stimulate tissue repair and vascular remodeling 
seen in COPD. Angiopoietins are distinct molecules that act 
in association with VEGF at different stages of angiogenic 
processes in several biological systems (McDonald 1999; 
Ribatti et al 2000; Yancopoulos et al 2000). The regulation 
of angiogenesis is determined by a dual, yet opposing bal-
ance of angiogenic and angiostatic factors that promote or 
inhibit neovascularization, respectively, not yet elucidated 
in detail in COPD.
In addition to studying VEGF expression in bronchial and 
bronchiolar walls, Kranenburg and coworkers also investi-
gated VEGF staining in the alveolar spaces and pulmonary 
vessels (Kranenburg et al 2005a). The authors found that the 
epithelial and endothelial cells in the alveolar spaces and the 
distal airways were intensively positive for VEGF in patients 
with COPD suggesting a paradoxical role for this angiogenic 
factor (Knox et al 2005; Postma and Times 2006). This role 
seems different between bronchi and air spaces in COPD – a 
protective one in the alveolus but a detrimental function in 
the bronchi and bronchioles.
Vascular remodeling in COPD
COPD is associated with structural and functional changes in 
the pulmonary circulation that commence at an early stage. 
Pulmonary vascular remodeling leading to pulmonary hyper-
tension and cor pulmonale is a characteristic feature of COPD 
(Wright et al 1983; Wilkinson et al 1988). Hypoxia has been 
classically considered the major pathogenic mechanism 
of these changes (Nilson et al 2004). However, structural 
abnormalities of pulmonary arteries are not exclusive of 
advanced COPD, as they have been shown also in patients 
with mild COPD without arterial hypoxemia and even in 
smokers with normal lung function (Barbera et al 1994). In 
agreement with this notion, recent studies suggest that the 
natural history of pulmonary hypertension in COPD might 
commence at moderate degrees of disease severity (Kessler 
et al 2001). In addition, previous observations have indicated 
that muscular and bronchiolar arteries have increased adven-
titial inﬁ  ltration of CD8+ T lymphocytes and have intimal 
thickening that is correlated with the amount of total collagen 
deposition (Santos et al 2002). It has been demonstrated that 
VEGF could play a role in the pathogenesis of the intimal 
cell proliferation shown in pulmonary arteries of smokers and 
patients with mild COPD (Peinado et al 1999). This concept International Journal of COPD 2007:2(4) 456
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has promoted a growing interest in clarifying the role of 
VEGF at different stages of COPD. With this background in 
mind, the same group of investigators evaluated the expres-
sion of VEGF protein and mRNA in pulmonary arteries and 
lung tissue of smokers and patients with different degrees 
of COPD severity (Santos et al 2003). The results of this 
interesting study showed an increased expression of VEGF 
in pulmonary muscular arteries of patients with moderate 
COPD and also in smokers with normal lung function, as 
compared with nonsmokers, and that this expression is asso-
ciated with the enlargement of the arterial wall. In contrast, in 
patients with severe emphysema, the immunohistochemical 
expression of VEGF in pulmonary arteries and its protein 
content in lung tissue tends to be low, despite intense vas-
cular remodeling.
In order to further illuminate the pathobiology of pul-
monary vascular remodeling in COPD, the same group 
conducted a recently reported study to investigate whether the 
presence of vascular progenitor cells is related to endothelial 
function or the expression of angiogenic factors (Peinado 
et al 2006). They demonstrated the presence of these cells in 
the endothelial surface and the intimal space of pulmonary 
arteries of patients with COPD (Peinado et al 2006). The 
number of progenitor cells was associated with the response 
to hypoxic stimulus but also with the enlargement of the 
arterial wall suggesting that these cells might be involved in 
the mechanisms of pulmonary vessel repair and remodeling 
in COPD (Peinado et al 2006).
Furthermore, it has been recently suggested that VEGF 
might be involved in the pathogenesis of emphysema 
through apoptotic mechanisms (Kasahara et al 2001). 
Several experimental strategies in mice (Tang et al 2004a, 
Petrache et al 2006) and rats showed that chronic cigarette 
smoking and administration of a VEGF receptor blocker 
(Kasahara et al 2000; Tuder et al 2003) caused lung cell 
apoptosis and signiﬁ  cant airspace enlargement. It has been 
suggested that the lung microvascular endothelial cells 
(including the alveolar septal capillary cells) are particularly 
vulnerable and dependent on VEGF (Voelkel et al 2006) for 
their survival. Apoptosis of endothelial, leading to the loss 
Figure 1 Angiogenetic process in COPD. The angiogenetic pathway is stimulated when inﬂ  amed, hypoxic, or injured tissues produce and release different angiogenetic 
promoters. Loss of the pulmonary vascular bed has been suggested to lead to the formation of new vessels comprising lung tissue remodeling-like changes in mucosal 
tissue, ﬁ  ber types and/or ﬁ  brosis, pulmonary and systemic inﬂ  ammation, lung vascular remodeling, and angiogenesis.
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of capillaries may well be a central mechanism in patients 
with emphysema and muscle wasting. For example, Tang 
and coworkers (Tang et al 2004b) demonstrated that skeletal 
muscle-speciﬁ  c conditional knockout of VEGF in mice 
caused endothelial cell apoptosis and capillary loss at the 
sites of VEGF knockout. These observations support the 
concept of capillary loss via endothelial cell apoptosis in 
animal models of emphysema (Yamato et al 1996; Plataki 
et al 2006).
Growth factors
Vascular endothelial growth factor 
(VEGF)
One of the pivotal proteins involved in vascular remodeling 
is VEGF. The VEGF family (VEGF-A to F) are heparin 
binding proteins and act via their afﬁ  nity transmembrane 
receptors VEGFR1(Flt-1) and VEGFR-2 (KDR-Flk-1) 
(Cross and Claesson-Welsh 2001). VEGF promotes an array 
of responses in the endothelium including hyperpermeability, 
endothelial cell proliferation, and angiogenesis with new 
vessel tube formation in vivo (Cross and Claesson-Welsh 
2001; Voelkel et al 2002). VEGF expression can be induced 
under a number of pathophysiological conditions including 
pulmonary hypoxia and pulmonary hypertension (Tuder 
et al 1995; Voelkel et al 2002). Both hypoxia and pulmonary 
hypertension are pathological features often seen in patients 
with advanced COPD (Pauwels and Rabe 2004). VEGF and 
its receptors are involved in many processes in COPD includ-
ing bronchial wall remodeling, emphysema, and pulmonary 
hypertension.
A number of conditions relevant to COPD have been 
shown to increase VEGF expression and release including 
cigarette smoke (Ribatti et al 2000; Yancopoulos et al 2000), 
hypoxia (Ribatti et al 2000; Yancopoulos et al 2000) and 
cytokines such as TGF-β (Wen et al 2003). However, the 
signiﬁ  cance of VEGF expression pattern in the bronchial 
vessels in COPD and its role to the pathology of this sys-
temic disease is still not elucidated. An increased bronchial 
vasculature would increase inﬂ  ammatory cell trafﬁ  cking 
and exudation and transudation of mediators, particularly if 
vascular permeability is altered. The increased vasculature 
could also contribute to airway hyper responsiveness by 
supporting the enlarged airway smooth muscle mass which 
is a feature of COPD. Previous animal (Siafakas et al 2001) 
and human studies in COPD patients (Alexopoulou et al 
2005) exhibited upregulation of VEGF levels in the dia-
phragm. This up regulation of VEGF expression in COPD 
compared with control subjects suggested an enhancement 
of angiogenesis in the cardinal respiratory muscle. A recent 
study by Kranenburg et al (2005) showed increased staining 
of VEGF in bronchial smooth muscle consistent with this 
hypothesis. The authors found increased VEGF expression 
and its receptors in 14 ex-smoking patients with COPD 
in comparison with 14-smoking healthy control subjects 
(Kranenburg et al 2005). TGF-β staining in the bronchiolar 
epithelium also correlated with VEGF in the same patients. 
They postulated that VEGF and its receptor system may 
contribute to the maintenance of endothelial and epithelial 
cell viability in response to injury suggesting that TGF-β and 
VEGF represents a complex molecule contributing to airway 
remodeling in COPD (Knox et al 2005).
Angiopoietin-1 (Ang-1)
The endothelial cell-speciﬁ  c growth factors, VEGF and 
Ang-1 have potent and clinically relevant actions on the 
microvasculature (Yancopoulos et al 2000; McDonald 2001). 
Ang1 is essential for the development of the vasculature but 
in a different way than VEGF. Mice lacking Ang1, or its tyro-
sine kinase receptor Tie –2, die because primitive endothelial 
cells tubes do not evolve into mature vessels (Alexopoulou 
et al 2005). The ability of Ang1 to block plasma leakage 
without producing angiogenesis may be therapeutically 
advantageous. This antileakage action of Ang1 offers a pos-
sible new strategy for reducing airway edema in COPD and 
asthma. Furthermore, because VEGF and Ang1 have additive 
effects in promoting angiogenesis but opposing effects on 
vascular permeability, they could be used together to avoid 
the formation of leaky vessels in therapeutic angiogenesis. 
The role of this novel mediator in the pathogenetic pathway 
of COPD remains to be further elucidated.
Fibroblast growth factors (FGFs)
In view of their important role in chronic inﬂ  ammation, 
ﬁ  brosis, and repair of various tissues, including the lung, 
FGFs (Sato et al 1995), may well play a pivotal role in airway 
and vascular walls remodeling (Holgate 1997; Szebenyi and 
Fallon 1999). FGFs exert their biologic effects via binding to 
four high-afﬁ  nity FGF transmembrane tyrosine-kinase recep-
tors (FGFR) (Werner 1998). Distinct FGF subtypes bind with 
different afﬁ  nity to the various FGFR. In the lung as well as 
in the vascular system, FGFs have been implicated in several 
pathologic conditions. FGF-1 and FGFR-1 were shown to be 
upregulated during the development of lung ﬁ  brosis (Barrios 
et al 1997). Moreover, vascular remodeling in response to 
increased blood pressure is associated with elevated levels 
of basic FGF (Singh et al 1998; Bryant et al 1999).International Journal of COPD 2007:2(4) 458
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Recent investigations (Kranenburg et al 2002; Shute et al 
2004; Kranenburg et al 2005b; Guddo et al 2006) support the 
notion that in patients with COPD, increased vascular expres-
sion of FGF-1, FGF-2, and FGFR-1 could participate in an 
autocrine and/or a complex growth factor–cytokine interac-
tive manner in regulating the process of pulmonary vascular 
remodeling. These data further support the hypothesis that 
COPD is associated with pulmonary vascular remodeling and 
that the FGF–FGFR system contributes to the pathogenesis 
and severity of the disease (Kranenburg et al 2002; Shute et al 
2004; Kranenburg et al 2005b; Guddo et al 2006).
Epidermal growth factor (EGF)
The epidermal growth factor and its receptor (EGFR) auto-
crine pathway contribute to a number of processes important 
to cell proliferation, apoptosis, and angiogenesis. EGF plays 
a critical role in airway mucus secretion from goblet cells 
and submucosal glands and appears to mediate the mucus 
secretory response to several secretagogues, including 
oxidative stress, cigarette smoke and inﬂ  ammatory cytokines 
(de Boer et al 2006).
Chemokines
Selective leukocyte trafﬁ  cking and recruitment is primarly 
regulated by a speciﬁ  c family of small proteins called “che-
mokines”. Over 50 different chemokines are now recognized, 
and they activate up to 20 different surface receptors (Rossi 
and Zlotnik 2000) playing a cardinal role in orchestrating 
inﬂ  ammatory and immune cells to target organs (Olson and 
Ley 2002). Airway inﬂ  ammation in COPD has been reported 
to consist mainly of CD68+ macrophages, elastase-positive 
neutrophils and CD8+ T cells. Physiologically, each of these 
cells is activated by a speciﬁ  c subset of chemokines.
Molecules that originally promote angiogenesis include 
members of the CXC chemokine family, characteristically 
heparin binding proteins which on structural level have four 
highly conserved cysteine amino acid residues, with the 
ﬁ  rst two cysteines separated by one nonconserved amino 
acid residue. CXC chemokines display unique diverse 
roles in the regulation of angiogenesis resulting from dis-
similarity in structure. Therefore, members that contain in 
the NH2-terminus a three amino-acid motif (ELR) such 
as IL-8/CXCL8, epithelial neutrophil activating protein 
(ENA)-78/CXCL5, growth- related genes (GROs, α,β,γ/
CXCL1,2,3), granulocyte chemotactic protein (GCP)-2/
CXCL6 and neutrophil activating protein (NAP)-2/CXCL7, 
originally promote angiogenesis (Strieter et al 2004). There 
are two candidate CXC chemokine receptors that mediate 
this effect: CXCR1 and CXCR2 (Strieter et al 2004). In 
the airway inﬂ  ammation of COPD, neutrophils are mainly 
attracted by CXCL8 via CXCR1 and CXCR2. In addition, 
CXCR1 is involved in neutrophilic degranulation, protease 
release and oxidative stress. Hence, these chemokines are 
thought to be involved in the pathogenesis of COPD. There 
is particular interest in identifying chemokines in COPD, 
as small molecule chemokine receptor inhibitors are now 
in development for COPD therapy (Barnes 2002; Panina-
Bordignon and D’Ambrosio 2003; Barnes and Stockley 
2005; Barnes 2006).
By contrast, other members of the CXC chemokine family 
that do not contain the angiogenic ELR motif (ELR-) behave 
as potent inhibitors of angiogenesis. Platelet factor-4 (PF-4)/
CXCL4 was the ﬁ  rst chemokine described to inhibit aberrant 
angiogenesis. Furthermore, the angiostatic ELR- members 
of the CXC chemokine family include the interferon (IFN)-γ 
inducible protein (IP)-10 /CXCL10, monokine induced by 
IFN-γ (MIG)-CXCR3 and IFN-γ Inducible T-cell-α chemoat-
tractant (ITAC)/CXCL11. All three chemokines activate 
CXC chemokine receptor CXCR3, although I-TAC has 
the highest activity (Jeffery 2001a). Table 2 summarizes 
the studied angiogenic and angiostatic mediators in COPD. 
The role of cardinal angiogenic / angiostatic chemokines in 
the pathogenesis of COPD is described below.
IL-8/CXCL8
The CXC L8 is a potent, selective chemoattract of neutrophils 
and is present in high concentrations in induced sputum of 
patients with COPD (Keatings et al 1996; Yamamoto et al 
1997). Furthermore, there is a good correlation between the 
levels of IL-8 and the degree of neutrophilia in sputum. IL-8 
levels are also increased in BAL ﬂ  uid of patients with COPD 
(Pesci et al 1998). The concentrations of IL-8 are signiﬁ  cantly 
higher in smokers with emphysema than in matched smok-
ers without airﬂ  ow limitation, whereas the concentrations of 
other CXC chemokines in BAL do not appear to discriminate 
between these groups (Tanino et al 2002).
The cellular source of IL-8 in COPD is not completely 
clear and may be secreted by macrophages, neutrophils, 
and airway epithelial cells. It signals through two receptors: 
a low – afﬁ  nity CXCR1 speciﬁ  c for IL-8 that is involved 
in neutrophil activation and a high afﬁ  nity that is activated 
by two other major angiogenic CXC chemokines, such as 
GRO-α and ENA-78, which may also be increased in COPD 
(Traves et al 2002). Therefore, antagonism of CXCR2 may 
be a more effective strategy, while a monoclonal antibody 
to IL-8 has been developed and has been tested in COPD International Journal of COPD 2007:2(4) 459
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without reported success (Yang et al 1999). An inhibitor of 
CXCR2, such as SB225002, may prove to be particularly 
beneﬁ  cial and is now entering in clinical trials (Hay and Sarau 
2001; Widdowson 2004). These drugs may also be useful in 
exacerbations of COPD when CXCR2 are upregulated in the 
airways (Qiu et al 2003) and in mucus hypersecretion which 
may be mediated via CXCR2 in experimental virus-induced 
exacerbations (Miller et al 2003).
Growth-related oncogene-α (GRO-α/CXCL1)
It is another angiogenic chemokine implicated in the 
pathogenesis of COPD. GRO-α is secreted by alveolar 
macrophages and airway epithelial cells in response to 
stimulation with TNF-α and IL-17 (Jones and Chan 2002) 
and activates neutrophils, monocytes, basophils, and T 
lymphocytes via CXCR2. The concentrations of GRO-α 
have been found markedly elevated in induced sputum and 
BAL of patients with COPD compared with normal smokers 
and nonsmokers (Traves et al 2002). It is possible that the 
increased chemotactic response of monocytes to GRO-α 
is one of the mechanisms leading to increased numbers of 
alveolar macrophages in the lungs of patients with COPD 
(Retamales et al 2001) and could be one of the molecular 
mechanisms of susceptibility to cigarette smoking.
Epithelial cell-derived neutrophil-activating peptide-
78 (ENA-78/CXCL5)
It is derived predominantly from epithelial cells and also acti-
vates CXCR2 (Imaizumi et al 1997), although monocytes do 
not appear to show an increased chemotactic response to this 
chemokine as they do to GRO-α (Traves et al 2004). ENA-78 
is increased in BAL ﬂ  uid of COPD patients compared with 
normal subjects, but no difference has been found between 
patients with emphysema and normal smokers (Traves et al 
2004). A signiﬁ  cant increase in expression of ENA-78 has 
been reported in epithelial cells during exacerbations of 
COPD (Qiu et al 2003).
CXC3 chemokines
The CXC3 chemokine family behaves as potent inhibitors 
of angiogenesis. T cells in peripheral airways of COPD 
patients showed increased expression of CXCR3. CXCR3 is 
expressed on T lymphocytes, particularly of the CD8+ sub-
type. There is increased expression of IP-10 by bronchiolar 
epithelial cells and airway smooth muscle cells, and this 
could therefore contribute to the accumulation of the CD8+ 
cells, which preferentially express CXCR3 (Chrysofakis 
et al 2004; Tzanakis et al 2004). It is of interest that inter-
feron-γ stimulates dendritic cells to produce IP-10 and Mig, 
which enhance their ability to attract CD8+ cells (Barnes 
and Stockley 2005). Alveolar macrophages also have the 
capacity to produce IP-10 and Mig and thus attract CD8+ T 
cells (Barnes 2002, Barnes 2006). These data suggest that 
CXCR3 antagonists might also be useful as a therapeutic 
approach in COPD.
Monocyte chemoattractant protein or eotaxin 
(MCP-1/ CCL2)
CC-chemokines are also involved in COPD. There is 
increased expression of monocyte chemotactic protein-1 
and its receptor cysteine-cysteine receptor (CCR)2 in mac-
rophages and epithelial cells from COPD patients and this 
may play a role in recruitment of blood monocytes to the 
lungs of COPD patients (Barnes 2002; Saetta et al 2002). 
Table 2 List of studied angiogenic and angiostatic mediators in COPD
Systematic name  Previous name  Chemokine receptor  Activity
CXC Chemokines    
CXCL1 GRO-α CXCR2>CXCR1  angiogenic
CXCL5 ENA-78  CXCR2  angiogenic
CXCL8 IL-8  CXCR2,  CXCR1  angiogenic
CXCL9 MIG CXCR3  angiostatic
CXCL10 IP-10  CXCR3  angiostatic
CXCL11 I-TAC CXCR3  angiostatic
CC Chemokines    
CCL2 MCP-1/Eotaxin  CCR2  angiogenic
Growth factors    
VEGF   Flt-1,  KDR/Flk-1  angiogenic
bFGF   FGFR-1  angiogenic
Angiopoietin-1   Tie-2  angiogenic
HGF     angiogenic
EGF     angiogenicInternational Journal of COPD 2007:2(4) 460
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This suggests that CCR2 antagonists may be of use and small 
molecule inhibitors are in clinical development (Rose et al 
2003; Barnes 2004).
Conclusions
COPD is associated with structural and functional changes in 
the pulmonary circulation that commence at an early stage, 
as they have been shown also in patients with mild COPD 
without arterial hypoxemia and even in smokers with normal 
lung function. Angiogenesis and microvascular remodeling 
not only result in more or larger blood vessels in the airway 
mucosa but also in functionally abnormal.
Various cells (macrophages, lymphocytes, mast cells, 
ﬁ  broblasts, and their mediators) participating in the inﬂ  am-
matory process of COPD can stimulate vessel growth. 
Pro-inflammatory cytokines, such as tumour necrosis 
factor (TNF)-α, may also have angiogenic in addition to 
proinﬂ  ammatory activity. Increased blood ﬂ  ow in COPD 
itself may stimulate angiogenesis through shear stresses 
on the endothelium. Growth factors like epidermal growth 
factor (EGF), FGF and VEGF stimulate tissue repair and 
vascular remodeling seen in COPD. However, the regula-
tion of angiogenesis is determined by a dual, yet opposing 
balance of angiogenic and angiostatic factors that promote 
or inhibit neovascularization, respectively, not yet eluci-
dated in detail in COPD.
Recently, it has been demonstrated that VEGF could 
play a role in the pathogenesis of the intimal cell prolifera-
tion shown in pulmonary arteries of smokers and patients 
with mild COPD. This concept has promoted a growing 
interest in clarifying the role of VEGF at different stages 
of COPD. An increased expression of VEGF in pulmonary 
muscular arteries of patients with moderate COPD and also 
in smokers with normal lung function, has been shown, and 
its expression was associated with the enlargement of the 
arterial wall. In contrast, in patients with severe emphy-
sema, VEGF content tended to be low, despite intense 
vascular remodeling. Furthermore, it has been lately sug-
gested that VEGF might be involved in the pathogenesis 
of emphysema through apoptotic mechanisms. Apoptosis 
of endothelial, leading to the loss of capillaries may well 
be a central mechanism in patients with emphysema and 
muscle wasting.
In conclusion, the pathobiology of angiogenesis and vas-
cular remodeling in COPD is not fully understood. Because 
endothelium plays a key role in regulating cell growth in vessel 
wall, it has been hypothesized that endothelial dysfunction 
might be an initiating event that promotes vessel remodeling 
in COPD. Progenitor cells of bone marrow origin migrate to 
injured vessels, where they may contribute to endothelial main-
tenance and vessel remodeling through VEGF-related signals. 
Future studies should be focused in elucidating the role of 
progenitor cells in vascular changes occurring in patients with 
COPD. Advances in understanding the pathogenesis of COPD 
have the potential for identifying new therapeutic targets that 
could alter the natural history of the disease.
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